An economic perspective on policy to reduce antimicrobial resistance

Social Science and Medicine

Volumn 46, Issue 1, 1998, Pages 29-38

  Coast, J ^a   Smith, R D ^b   Millar, M R ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Antimicrobial resistance; Environmental policy; Externality; Health economics

Indexed keywords

ANTIINFECTIVE AGENT;

DRUG RESISTANCE; ECONOMIC PERSPECTIVE; HEALTH POLICY; POLICY IMPLICATION;

ANTIBIOTIC RESISTANCE; ARTICLE; COST BENEFIT ANALYSIS; HEALTH CARE POLICY; HEALTH ECONOMICS; HUMAN; INFECTION; MEDICAL RESEARCH;

COMMUNICABLE DISEASE CONTROL; COSTS AND COST ANALYSIS; DRUG AND NARCOTIC CONTROL; DRUG RESISTANCE, MICROBIAL; FEES AND CHARGES; GREAT BRITAIN; HUMANS; LEGISLATION, DRUG; TAXES;

EID: 0031983732     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0277-9536(97)00132-9     Document Type: Article

References (37)

1. Aaron H. J. (1992) The Oregon experiment. In Rationing America's Medical Care: The Oregon Plan and Beyond, eds M. A. Strosberg, J. M. Weiner, R. Baker and I. A. Fein, pp. 107-111. Brookings Institution, Washington, DC.
2. American Society for Microbiology (1995) Report of the ASM task force on antibiotic resistance. Antimicrobial Agents and Chemotherapy 10, 1-23.
3. Bevan, G., Bartlett, W. and Murphy, S. (1995) Transactors, property rights and competition in the NHS market. Paper presented at the Third European Conference on Health Economics, Stockholm, Sweden.
4. Broome, J. (1992) Counting the Cost of Global Warming. White Horse Press, Cambridge.
5. Burne, J. (1996) A spoonful of oil makes the medicine unwanted. Independent 30 January, Part 2, pp. 4-5.
6. Cannon, G. (1995) Superbug. Nature's Revenge. Virgin, London.
7. Coast, J., Donovan, J. L. and Frankel, S. J. (1996a) Priority Setting: The Health Care Debate. Wiley, Chichester.
8. Coast, J., Smith, R. D. and Millar, M. R. (1996b) Superbugs: should antimicrobial resistance be included as a cost in economic evaluation? Health Economics 5, 217-226.
9. Cox, R. A., Conquest, C., Mallaghan, C. and Marples, R. R. (1995) A major outbreak of methicillin resistant Staphylococcus aureus caused be a new phage-type (EMRSA-16). Journal of Hospital Infection 29, 87-106.
10. Davey, P. G., Bax, R. P., Newey, J., Reeves, D., Rutherford, D. and Slack, R. (1996) Growth in the use of antibiotics in the community in England and Scotland in 1980-93. British Medical Journal 312, 613.
11. Evans, R. G. (1984) Strained Mercy: The Economics of Canadian Health Care. Butterworths, Toronto.
12. Garrett, L. (1995) Mutating microbes. Independent 17 September, pp. 64-65.
13. Goldmann, D. A., Weinstein, R. A., Wenzel, R. P., Tablan, O. C., Duma, R. J. and Gaynes, R. P. (1996) Strategies to prevent and control the emergence and spread of antimicrobial resistant microorganisms in hospitals. A challenge to hospital leadership. Journal of the American Medical Association 275(3), 234-240.
14. Gonzales, R. and Sande, M. (1995) What will it take to stop physicians from prescribing antibiotics in acute bronchitis? Lancet 345, 665.
15. Grossman, M. (1972) The Demand for Health: A Theoretical and Empirical Investigation. Columbia University Press, New York.
16. Halkos, G. E. (1993) Sulphur abatement policy. Implications of cost differentials. Energy Policy 21, 1035-1043.
17. Halkos, G. E. (1995) Economic incentives for optimal sulfur abatement in Europe. Energy Sources 17, 517-534.
18. Hodge, I. (1995) Environmental Economics. MacMillan, Basingstoke.
19. Hollis-Triantafillou, J. (1996) Over the counter antibiotics. British Medical Journal 312, 644.
20. Hunt, L. (1996) Perfect culture for a "superbug". Independent 27 Feb, Part 2, p. 7.
21. Kubin, C. M. (1993) Resistance to antimicrobial drugs - a worldwide calamity. Annals of Internal Medicine 118, 557-561.
22. Levy, J. (1990) Antibiotic resistance in Europe and the current use of antibiotics in severe pediatric infections. Scandinavian Journal of Infectious Diseases 73, 23-29.
23. Levy, S. B. (1992) The Antibiotic Paradox. How Miracle Drugs are Destroying the Miracle. Plenum Press, New York.
24. Murray, B. E. (1994) Can antibiotic resistance be controlled? New England Journal of Medicine 330(17), 1229-1230.
25. Neu, H. C. (1992) The crisis in antibiotic resistance. Science 257, 1064-1073.
26. Pearce D. W. and Turner R. K. (1990) Economics of Natural Resources and the Environment. Harvester Wheatsheaf, London.
27. Pringle, M. (1995) Access to antibiotics: a case for a change in category. Journal of Antimicrobial Chemotherapy 36, 577-579.
28. Reeves, D. S. and Lewis, D. A. (1995) Over the counter anti-infectives - of benefit to whom? Journal of Antimicrobial Chemotherapy 36, 579-583.
29. Smith, R. D., Coast, J. and Millar, M. R. (1996) Over-the-counter antimicrobials: the hidden costs of resistance. Journal of Antimicrobial Chemotherapy 37, 1031-1032.
30. Steinbrook, R. and Lo, B. (1992) The Oregon Medicaid demonstration project - will it provide adequate medical care? New England Journal of Medicine 326, 340-344.
31. Tietenberg, T. H. (1990) Economic instruments for environmental regulation. Oxford Review of Economic Policy 6(1), 17-33.
32. Tomasz, A. (1994) Multiple-antibiotic resistant pathogenic bacteria. A report on the Rockefeller University workshop. New England Journal of Medicine 330(17), 1247-1251.
33. Turner, R. K., Pearce, D. and Bateman, I. (1994) Environmental Economics. An Elementary Introduction. Harvester Wheatsheaf, London.
34. U.S. Congress, Office of Technology Assessment (1995) Impacts of Antibiotic-Resistant Bacteria. OTA-H-629. U.S. Government Printing Office, Washington, DC.
35. Williams, J. D. (1986) Antibiotic policy . Scandinavian Journal of Infectious Diseases 49, 175-181.
36. Winebrake, J. J., Farrell, A. E. and Bernstein, M. A. (1995) The Clean Air Act's sulfur dioxide emissions market: estimating the costs of regulatory and legislative intervention. Resource and Energy Economics 17, 239-260.
37. Working Party of the British Society for Antimicrobial Chemotherapy (1994) Working Party Report. Hospital antibiotic control measures in the UK. Journal of Antimicrobial Chemotherapy 34, 21-42.